SNDX: Syndax Pharmaceuticals, Inc.
About
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Current Value
$15.601 Year Return
Current Value
$15.601 Year Return
Key Details
Market Cap
$1.35B
P/E Ratio
-4.34
1Y Stock Return
2.87%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
3.7
Strategies that include SNDX
Stock's related to SNDX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KN | 45.96% | $1.60B | +12.19% | 0.00% |
| PGY | 45.36% | $634.91M | -45.99% | 0.00% |
| ALEC | 44.82% | $377.04M | -19.46% | 0.00% |
| BRSP | 44.25% | $806.64M | -3.86% | 12.20% |
| PGEN | 44.23% | $228.91M | -28.00% | 0.00% |
| FBNC | 44.07% | $1.87B | +46.57% | 1.95% |
| SCL | 43.53% | $1.69B | -6.79% | 2.01% |
| TRST | 43.51% | $691.41M | +34.26% | 3.98% |
| VCEL | 43.47% | $2.76B | +55.60% | 0.00% |
| NWBI | 43.43% | $1.84B | +30.71% | 5.56% |
| GPRO | 42.80% | $179.52M | -67.23% | 0.00% |
| STBA | 42.80% | $1.61B | +49.48% | 3.18% |
| PLYM | 42.69% | $842.88M | -11.32% | 5.12% |
| ONIT | 42.63% | $240.15M | +14.44% | 0.00% |
| NGVT | 42.46% | $1.67B | +18.26% | 0.00% |
| RDFN | 42.46% | $1.01B | +24.16% | 0.00% |
| RCUS | 42.34% | $1.33B | +5.07% | 0.00% |
| VRTS | 42.12% | $1.63B | +19.88% | 3.42% |
| HONE | 41.99% | $572.67M | +17.97% | 2.43% |
| IDYA | 41.92% | $2.24B | -15.21% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FWONK | -<0.01% | $20.20B | +25.99% | 0.00% |
| CCEC | -0.04% | $1.02B | +28.03% | 3.26% |
| UONEK | 0.07% | $46.08M | -77.68% | 0.00% |
| HIHO | -0.11% | $8.63M | 0.00% | 6.12% |
| NXTC | 0.12% | $36.69M | +6.50% | 0.00% |
| PEP | 0.22% | $215.02B | -6.60% | 3.35% |
| BYRN | -0.23% | $479.70M | +295.19% | 0.00% |
| GIS | -0.24% | $34.85B | -2.91% | 3.78% |
| NEUE | -0.40% | $40.93M | -34.13% | 0.00% |
| NGL | -0.40% | $572.94M | +5.60% | 0.00% |
| TH | -0.40% | $839.02M | -24.49% | 0.00% |
| VHC | -0.46% | $19.06M | -38.36% | 0.00% |
| LITB | 0.50% | $35.48M | -75.45% | 0.00% |
| AXS | 0.50% | $7.14B | +55.12% | 2.06% |
| CRVO | 0.64% | $83.20M | +2.86% | 0.00% |
| PRPO | -0.76% | $9.10M | -13.65% | 0.00% |
| PDD | 0.79% | $163.43B | +0.29% | 0.00% |
| AIFU | -0.83% | $67.49M | -83.02% | 0.00% |
| IMRN | 0.84% | $10.31M | -5.04% | 0.00% |
| ACGL | 0.88% | $36.00B | +16.84% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTCT | -41.62% | $42.61M | +353.33% | 0.00% |
| MNOV | -28.15% | $93.19M | +2.15% | 0.00% |
| HUSA | -12.79% | $16.69M | -11.56% | 0.00% |
| WM | -11.96% | $87.92B | +27.58% | 1.34% |
| PRT | -11.02% | $48.72M | -16.56% | 10.33% |
| SE | -11.01% | $60.12B | +197.12% | 0.00% |
| MCK | -10.27% | $78.15B | +35.51% | 0.42% |
| SYPR | -9.22% | $32.23M | -26.32% | 0.00% |
| CORZ | -7.85% | $4.60B | +3,201.26% | 0.00% |
| NPWR | -7.28% | $972.21M | +24.83% | 0.00% |
| SOLV | -7.26% | $11.58B | -16.19% | 0.00% |
| CME | -6.97% | $82.76B | +9.21% | 1.98% |
| WHLM | -6.95% | $17.64M | -29.34% | 0.00% |
| GAN | -6.35% | $83.39M | +21.19% | 0.00% |
| PGR | -6.18% | $149.10B | +57.29% | 0.45% |
| K | -4.99% | $27.77B | +52.50% | 2.79% |
| STG | -4.68% | $35.67M | +7.92% | 0.00% |
| PG | -4.62% | $402.15B | +14.14% | 2.33% |
| LUMO | -3.78% | $37.45M | +41.97% | 0.00% |
| CAH | -3.61% | $28.64B | +12.14% | 1.70% |
ETF's related to SNDX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 58.90% | $6.58B | 0.35% |
| IBB | 56.81% | $6.66B | 0.45% |
| PBE | 53.98% | $258.53M | 0.58% |
| GNOM | 53.90% | $70.59M | 0.5% |
| PTH | 53.58% | $143.31M | 0.6% |
| IWC | 53.50% | $933.99M | 0.6% |
| RSPA | 53.48% | $273.87M | 0% |
| XPH | 53.03% | $157.87M | 0.35% |
| EZM | 52.24% | $823.84M | 0.38% |
| DFAT | 52.02% | $11.16B | 0.28% |
| REM | 51.99% | $632.41M | 0.48% |
| IWO | 51.89% | $12.56B | 0.24% |
| VTWO | 51.86% | $12.38B | 0.1% |
| IWM | 51.72% | $75.73B | 0.19% |
| PINK | 51.06% | $161.15M | 0.5% |
| PSC | 50.81% | $702.17M | 0.38% |
| IWS | 50.65% | $13.85B | 0.23% |
| NUSC | 50.50% | $1.27B | 0.31% |
| ESML | 50.32% | $1.90B | 0.17% |
| MDYV | 50.30% | $3.25B | 0.15% |
News
Yahoo
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain pediatric patients with an aggressive form of acute leukemia.
Yahoo
The approval is based on the Phase I/II AUGMENT-101 trial, which included 104 patients with acute leukaemia.
Finnhub
Syndax Announces FDA Approval of Revuforj® , the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation ...
Finnhub
WALTHAM - Syndax Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Revuforj as the first and only menin inhibitor for the treatment of relapsed or refractory ...
Yahoo
Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (ND
Finnhub
Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj® as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.